Significant Opportunity Exists for Second-Line Therapies in Neuropathic Pain Market, According to a New Report from Decision Resources
Familiarity With Drug Treatment Options Will Vary By Region and Clinical Experience, According to a Report From Decision Resources
A Biomarker for the Diagnosis of Alzheimer’s Disease Will Have the Largest Impact on Drug Sales Among the CNS Markets, According to a New Report from Decision Resources
Emerging Nonstimulant Drugs Will Earn Less Than 15 Percent Share of the ADHD Market in 2017, According to a New Report from Decision Resources
Physicians Continue to Seek an Effective Maintenance Therapy to Treat the Disorder, According to a New Report from Decision Resources
Eastern Seaboard Has Seven of the Eight Regions with the Highest Prevalence in the U.S., According to a New Analytics Tool From Decision Resources
Most Important Factors Driving Nosocomial Pneumonia Prescribing in Hospitals Are Infectious Disease Consults and ATS/IDSA Guidelines
Percutaneous Coronary Intervention Has Become More Widely Available to Patients in Recent Years, According to a New Report from Decision Resources
Read More
DERMATOLOGISTS CONTINUE TO USE ENBREL OVER HUMIRA AS FIRST-LINE BIOLOGIC THERAPY FOR THE TREATMENT O
September 18, 2008
More Than 60 Percent of Dermatologists Familiar with the Drug Plan to Prescribe Stelara (Ustekinumab) Upon Its Anticipated Approval, According to a New Report from Decision Resources
METFORMIN, ACTOS AND JANUVIA ARE THE MOST COMMONLY PRESCRIBED AGENTS FOR THE TREATMENT OF PREDIABETE
September 17, 2008
Most Surveyed MCOs Allow Physicians a High Level of Prescribing Freedom for Treatment of Prediabetes, According to a New Report from Decision Resources
OVER TWO-THIRDS OF SURVEYED MCO PHARMACY DIRECTORS CITE TNF-ALPHA INHIBITORS AND ERYTHROPOIESIS-STIM
September 16, 2008
Following the Establishment of a Regulatory Pathway for Biosimilars in the U.S., Amgen is Most Vulnerable to Biosimilar Threat, According to a New Report from Decision Resources
CALIFORNIA SHOWS HIGH VARIABILITY IN TREATMENT RATES OF PSORIASIS
September 15, 2008
Los Angeles’ Near-Average Treatment Rate Presents Significant Opportunity for Pharmaceutical Companies, According to a New Analytics Tool From Decision Resources
EMERGING THERAPIES, INCLUDING BRISTOL-MYERS SQUIBB/MEDAREX'S IPILIMUMAB, WILL DRIVE GROWTH IN THE MA
September 15, 2008
Interviewed Experts Lack Confidence in Malignant Melanoma Cancer Vaccines as a Result of Recently Published Data, According to a New Report from Decision Resources
September 9, 2008
Market Will Experience Only Minimal Growth Through 2017, According to a New Report from Decision Resources
September 9, 2008
Premium Priced Drug Classes Account for 70 Percent of Market Sales, According to a New Report from Decision Resources
September 8, 2008
Increasing Diagnosis Rates Present Opportunities for Western Drug Companies Seeking to Penetrate Market, According to a New Report From Decision Resources
September 8, 2008
Dominance of Low-Molecular-Weight Heparins and Vitamin K Antagonists Will Be Curtailed by Novel Drugs, According to a New Report from Decision Resources
September 4, 2008
PPAR-Gamma Agonists’ Share of Second-Line Treatment is Declining, According to a New Report from Decision Resources
August 28, 2008
Competition From Chinese Makers Present Considerable Challenge to Branded Western Drug Companies Seeking to Penetrate Market, According to a New Report From Decision Resources
August 28, 2008
Utah and Mississippi Rank Very Low in Treatment Rate for Asthma and Chronic Obstructive Pulmonary Disease, According to a New Analytics Tool From Decision Resources
August 26, 2008
Most Surveyed MCO Pharmacy Directors Do Not Place Cost Control Measures on Branded Antiretroviral Drugs, According to a New Report from Decision Resources
August 21, 2008
Personalized Medicine Has the Potential for Good and Bad, According to a New Report from Decision Resources
August 18, 2008
Physician Treatment Patterns and Drivers Will Vary Based on a Drug’s Safety, Efficacy and Cost
August 14, 2008
Massachusetts, Maine and Vermont Have the Highest Percentages of Dyslipidemia Patients Who Have Prescription Drug Coverage but Are Currently Untreated, According to a New Analytics Tool From Decision Resources
August 13, 2008
Expected Approvals of Biologic Agents Will Expand Treatment Options for Patients Who Fail Conventional Drug Treatment, According to a New Report from Decision Resources
August 12, 2008
Owing to Well-Established and Effective Insulin-Based Therapies, Market Growth Will be Modest Through 2017, According to a New Report from Decision Resources
August 11, 2008
Decision Resources Introduces the Only Healthcare Analytics Tool that Assesses the Number of Insured Patients Who Have a Specific Disease, but Are Untreated
August 11, 2008
Lamictal Is the Leading Single-Agent in First-, Second- and Third-Line Therapy, According to a New Report from Decision Resources
EIGHTY-NINE PERCENT OF SURVEYED RHEUMATOLOGISTS SAY THEY WILL PRESCRIBE ROCHE/CHUGAI’S ACTEMRA FOR R
August 6, 2008
However, Pharmacy Directors Disagree About Formulary Inclusion for Key Emerging Biologic Agents That Will Launch for the Disease in the Next Few Years, According to a New Report from Decision Resources
SALES OF EMERGING NOVEL PAIN THERAPIES WILL REPRESENT MORE THAN ONE-FIFTH OF THE TOTAL PAIN DRUG MAR
August 5, 2008
Total Drug Market for Pain Will Reach More Than $47 Billion in 2023, According to a New Report from Decision Resources
A HIGH-DENSITY LIPOPROTEIN RAISING DRUG THAT HAS A LOWER DISCONTINUATION RATE THAN THAT OF EXTENDED
July 29, 2008
Crestor Will Remain the Clinical Gold Standard Drug Through 2016, According to a New Report from Decision Resources
LORI SILVER JOINS DECISION RESOURCES, INC. AS GENERAL COUNSEL
July 24, 2008
Formerly of Harvard University’s Office of General Counsel, Attorney Will be Responsible for All Legal Aspects of the Company
A DRUG THAT IMPROVES EXERCISE CAPACITY BY A GREATER PERCENTAGE THAN TRACLEER WOULD EARN A 48 PERCENT
July 22, 2008
Gleevec Will Achieve Clinical Gold Standard Status by 2011, According to a New Report from Decision Resources
ONLY 44.4 PERCENT OF PARKINSON’S DISEASE PATIENTS RECEIVE DRUG TREATMENT WITHIN ONE YEAR OF BEING DI
July 17, 2008
Few First-Line Patients Receive Dopamine Agonists Despite These Agents’ Ability to Stave Off Levodopa Treatment, According to a New Report from Decision Resources
BAPINEUZUMAB TO BECOME THE FIRST-TO-MARKET DISEASE-MODIFYING ALZHEIMER’S DRUG AFTER FLURIZAN’S DISCO
July 15, 2008
Up-to-Date Analysis of the Alzheimer’s Disease Market Now Available from Decision Resources
CURRENT AND EMERGING DRUGS CONTINUE TO STRUGGLE FOR PATIENT SHARE IN THE TREATMENT OF MAJOR DEPRESSI
July 15, 2008
Owing to Safety, Escitalopram Will Remain as the Clinical Gold Standard Treatment, According to a New Report from Decision Resources
UNITED STATES MARKET FOR THE TREATMENT OF PULMONARY SYMPTOMS OF CYSTIC FIBROSIS REACHED $397 MILLION
July 14, 2008
Prevalence of the Disease Will Rise As Improved Treatments Increase Patient Longevity, According to a New Report from Decision Resources
ALTHOUGH GENERIC EROSION LOOMS FOR RISPERDAL, THE DRUG REMAINS FIRST-LINE ANTIPSYCHOTIC IN THE TREAT
July 10, 2008
Other Atypicals Thrive by Capturing Specific Patient Populations, According to a New Report from Decision Resources
Read More
PRIMARY CARE PHYSICIANS’ PRESCRIPTIONS OF ARICEPT FOR ALZHEIMER’S DISEASE WILL DROP BY 20 PERCENT FO
July 9, 2008
Most Surveyed MCO Pharmacy Directors Will Move Razadyne and Razadyne ER from Tier 2 to Tier 3 When Generic Razadyne is Launched, According to a New Report from Decision Resources
A WEIGHT NEUTRAL ORAL ANTIDIABETIC DRUG WOULD EARN A 25 PERCENT PATIENT SHARE IN THE TYPE 2 DIABETES
July 1, 2008
Advantages in Efficacy and Safety Will Make Liraglutide the New Clinical Gold Standard Drug by 2011, According to a New Report from Decision Resources
BECAUSE OF ITS ABILITY TO GENERATE HIGHER TOTAL SALES IN THE UNITED STATES AND EUROPE, LUCENTIS WILL
June 26, 2008
A Drug with Superior Efficacy to Avastin at Improving Visual Acuity When Used with Laser Photocoagulation Would Earn a 20 Percent Patient Share, According to a New Report from Decision Resources
CHINA’S RENAL CELL CARCINOMA DRUG MARKET WILL GROW MORE THAN FIVE-FOLD BY 2012
June 25, 2008
Physician Treatment Patterns and Drivers Will Vary by Geographic Location, According to a New Report by Decision Resources
RENAL CELL CARCINOMA DRUG MARKET WILL MORE THAN DOUBLE OVER THE NEXT DECADE, RISING FROM $625 MILLIO
June 24, 2008
Multikinase Inhibitors, Most Notably Pfizer’s Sutent, Will Continue to Dominate the Market, According to a New Report from Decision Resources
NOVEL AGENTS WILL DRIVE THE HEPATITIS C VIRUS DRUG MARKET TO INCREASE NEARLY FIVE-FOLD TO MORE THAN
June 19, 2008
Hepatitis C Virus Market is One of the Most Active Areas of Infectious Disease Drug Development in Recent Years, According to a New Report from Decision Resources
LEXAPRO IS THE LEADING SINGLE AGENT IN FIRST- AND SECOND-LINE PATIENT SHARE FOR THE TREATMENT OF GEN
June 18, 2008
The Presence of Comorbid Depression Influences Physicians to Prescribe a Selective Serotonin Reuptake Inhibitor, According to a New Report from Decision Resources
LUNDBECK MAINTAINING PRESENCE IN ALZHEIMER’S DISEASE MARKET THROUGH STRATEGIC AGREEMENT TO MARKET MY
June 18, 2008
Physician Education Will be a Critical Step in the Adoption of Emerging Alzheimer’s Disease Therapies, According to a New Report from Decision Resources
GENERIC EROSION OF MARKET LEADING THERAPIES WILL CONSTRAIN GROWTH IN THE PARKINSON’S DISEASE DRUG MA
June 17, 2008
Modest Market Growth Will be Driven by the Arrival of Once-Daily Formulations of Dopamine Agonists, According to a New Report from Decision Resources
DECISION RESOURCES, INC. ACQUIRES MANHATTAN RESEARCH
June 17, 2008
Acquisition Expands Decision Resources, Inc.’s Portfolio to Include Global Physician and Consumer Digital Market Research
Read More
GOLIMUMAB AND ACTEMRA WILL BE TWO OF THE MOST SUCCESSFUL EMERGING NOVEL AGENTS IN THE RHEUMATOID ART
June 16, 2008
Among Currently Available Therapies, Enbrel and Humira Will Continue to Dominate the Market Through 2017, According to a New Report from Decision Resources
A DRUG WITH EFFICACY SUPERIOR TO THAT OF XENICAL AT INDUCING WEIGHT LOSS WOULD EARN A 40 PERCENT PAT
June 12, 2008
Advantages in Efficacy and Delivery Will Make Qnexa the New Clinical Gold Standard Drug by 2011, According to a New Report from Decision Resources
A DRUG WITH EFFICACY SUPERIOR TO THAT OF REMICADE AT INDUCING CLOSURE AND HEALING OF FISTULAS WOULD
June 11, 2008
Ustekinumab Will Earn a 5.4 Percent Patient Share by 2012, According to a New Report from Decision Resources
THE MONOCLONAL ANTIBODIES DRUG MARKET FOR THE TREATMENT OF CANCER WILL MORE THAN DOUBLE TO $16.7 BIL
June 10, 2008
Market Will be Driven by Increasing Use of Established Agents That Include Avastin, Erbitux, Rituxan/MabThera, According to a New Report from Decision Resources
EMERGENCE OF DRUGS FROM ELAN/WYETH, ELI LILLY, MYRIAD GENETICS AND MEDIVATION WILL DRIVE THE ALZHEIM
June 9, 2008
Sales of Currently Dominant Acetylcholinesterase Inhibitors Will Decrease by Nearly Half Over the Next Decade, According to a New Report from Decision Resources
DESPITE AVAILABILITY OF NUMEROUS GENERIC ANTIDEPRESSANTS, FOREST LABORATORIES’ LEXAPRO RETAINS LEADE
June 3, 2008
Wyeth’s Pristiq to Benefit from Key Change in Physicians’ Prescribing Patterns, According to a New Report from Decision Resources
GENERIC EROSION WILL CONSTRAIN PROSTATE CANCER DRUG MARKET, RESULTING IN ANNUAL MARKET GROWTH OF LES
June 3, 2008
However, Annual Market Growth Will Increase to 4.5 Percent from 2012 to 2017 Due to Emergence of Premium-Priced Drugs, According to a New Report from Decision Resources
FLORIDA IS THE STATE WITH THE HIGHEST NUMBER OF TYPE 2 DIABETICS WHO HAVE PRESCRIPTION DRUG COVERAGE
June 2, 2008
Decision Resources Introduces the Only Healthcare Analytics Tool that Assesses the Number of Insured Patients Who Have a Specific Disease, but Are Untreated
DRIVEN BY THE USE OF PREMIUM-PRICED BRANDED AGENTS, THE HIV DRUG MARKET WILL EXPERIENCE ROBUST ANNUA
June 2, 2008
New Products From Novel Drug Classes Are Addressing Key Unmet Needs for Highly Treatment-Experienced Patients, According to a New Report from Decision Resources
EMERGING COMBINATION THERAPIES, INCLUDING DRUGS FROM NOVARTIS/SCHERING-PLOUGH AND GLAXOSMITHKLINE/TH
May 28, 2008
Prevalent COPD Population Will Rise by Nearly 19 Percent as a Result of Increased Diagnosis Rates, According to a New Report from Decision Resources
CHINA’S TYPE 2 DIABETES DRUG MARKET WILL MORE THAN TRIPLE BY 2012
May 28, 2008
New Entries to China Drug Market to Garner More Than $270 Million in Combined Sales, According to a New Report by Decision Resources
NOVEL GLYCOPEPTIDES AND CEPHALOSPORINS WILL DRIVE THE HOSPITAL-ACQUIRED INFECTIONS DRUG MARKET THROU
May 21, 2008
Antibacterial Drug Development Faces Many Challenges Including Heightened Regulatory Scrutiny and Increasingly Stringent Reimbursement Policies, According to a New Report from Decision Resources
INCREASED COMPETITION, GENERIC EROSION AND COST CONSCIOUSNESS WILL CAUSE ASTHMA DRUG MARKET TO DECLI
May 19, 2008
However, Launch of New Agents Will Drive Growth in the Long-Acting Beta-Agonist/Inhaled Corticosteroid Class, According to a New Report from Decision Resources
DAIICHI SANKYO/ELI LILLY’S EFFIENT AND ASTRAZENECA’S TICAGRELOR MAY OFFER ADVANTAGES IN THE TREATMEN
May 15, 2008
Considerable Opportunity Remains for an Antiplatelet Therapy that, Combined with Aspirin, Causes Less Bleeding than the Combination of Plavix/Iscover and Aspirin, According to a New Report from Decision Resources
SIMVASTATIN LEADS PFIZER’S LIPITOR IN SECOND-LINE PATIENT SHARE FOR THE TREATMENT OF DYSLIPIDEMIA
May 13, 2008
Results from the ENHANCE Trial Impacting Physician Prescribing Patterns, According to a New Report from Decision Resources
LAUNCHES OF AT LEAST 15 NEW BIOLOGIC THERAPIES BY 2017 WILL EXPAND TREATMENT OPTIONS FOR IMMUNE AND
May 12, 2008
High-Priced Emerging Immunomodulators Will Drive Robust Market Growth Over the Next Decade, According to a New Report from Decision Resources
CURRENT AND EMERGING DRUGS HAVE NOT YET SHOWN AN ADVANTAGE IN SURVIVAL OVER VELCADE IN THE TREATMENT
May 8, 2008
A Drug Used in Combination with Velcade That Could Improve Overall Survival Would Earn a 45 Percent Patient Share, According to a New Report from Decision Resources
AVASTIN USED IN COMBINATION WITH DRUGS FROM BRISTOL-MYERS SQUIBB HAS ADVANTAGES IN SURVIVAL RATES OV
April 24, 2008
Avastin Used in Combination with Taxol and Paraplatin Will Become the Clinical Gold Standard Treatment by 2011, According to a New Report from Decision Resources
CURRENT AND EMERGING INSOMNIA DRUGS HAVE MINIMAL ADVANTAGES OVER SANOFI-AVENTIS’S AMBIEN IN CAUSING
April 24, 2008
However, Somaxon’s Silenor Will Replace Ambien as the Clinical Gold Standard for Insomnia in 2011, According to a New Report from Decision Resources
Read More
CONCERN FROM DOCTORS REGARDING THE CARDIOVASCULAR SAFETY OF GLAXOSMITHKLINE’S AVANDIA INCREASES NINE
April 22, 2008
Nearly Three-Quarters of Physicians Have Switched Patients to Merck’s Januvia, According to a New Report from Decision Resources
A DRUG THAT CARRIES A LOWER RISK OF WEIGHT GAIN THAN ASTRAZENECA’S SEROQUEL AND HAS ANTIMANIC AND AN
April 22, 2008
Seroquel’s Successor, Seroquel XR, Will Earn a 16 Percent Patient Share in the Bipolar Disorder Market by 2016, According to a New Report from Decision Resources
TIER STATUS IN PRIVATE INSURANCE PLANS FOR OTHER ANTIPSYCHOTIC DRUGS WILL REMAIN LARGELY UNCHANGED F
April 17, 2008
However, Up to 20 Percent of Surveyed MCO Medicaid Plans Will Remove Branded Antipsychotics From Formularies, According to a New Report from Decision Resources
BAYER/SCHERING-PLOUGH/SHIONOGI’S AVELOX HAS ADVANTAGES OVER LEVOFLOXACIN IN THE TREATMENT OF COMMUNI
April 17, 2008
Superior Bacteriological Eradication and Activity Against Antibiotic-Resistant Pathogens Earn Avelox Gold Standard Status Through 2016, According to a New Report from Decision Resources
PFIZER’S LYRICA DEMONSTRATES ADVANTAGES IN SUSTAINED EFFICACY OVER ELI LILLY’S SALES-LEADING CYMBALT
April 16, 2008
Milnacipran Seen as Most Promising Emerging Drug, According to a New Report from Decision Resources
NEW THERAPY BY MERCK IS POSITIONED TO EARN GOLD-STANDARD STATUS BY 2011 IN THE TREATMENT OF CHEMOTHE
April 9, 2008
Emerging Agent GlaxoSmithKline’s Rezonic Demonstrating Efficacy for Delayed Chemotherapy-Induced Nausea and Vomiting, According to a New Report from Decision Resources
A DRUG’S ABILITY TO ACHIEVE SUSTAINED VIRAL RESPONSE IN GENOTYPE 1 INFECTED PATIENTS IS THE MOST IMP
April 8, 2008
Surveyed Physicians Will Use Novel Drugs From Schering-Plough and Vertex/Johnson & Johnson in 75 Percent of Non-Responder Patients, According to a New Report from Decision Resources
MORE THAN HALF OF PATIENTS TREATED FOR BENIGN PROSTATIC HYPERPLASIA RECEIVE BOEHRINGER INGELHEIM’S F
April 7, 2008
Less Than 20 Percent of Patients Diagnosed with the Disease Receive Pharmacotherapy Within a Year of Their Diagnosis, According to a New Report From Decision Resources
CURRENT AND EMERGING DRUGS HAVE NO ADVANTAGE OVER ENBREL IN INHIBITING/SLOWING THE PROGRESSION OF RH
April 7, 2008
Although Some Emerging Therapies Hold Promise, Enbrel Will Remain the Clinical Gold Standard Through 2016, According to a New Report from Decision Resources
ASTELLAS/GLAXOSMITHKLINE’S VESICARE HAS ADVANTAGES OVER PFIZER’S DETROL LA/DETRUSITOL XL IN REDUCING
April 3, 2008
Superior Side-Effect Profile Earns Vesicare Gold Standard Status Over Sales-Leading Detrol LA/Detrusitol XL, According to a New Report from Decision Resources
Read More
CHINA’S GASTRIC CANCER DRUG MARKET TO NEARLY TRIPLE BY 2012
April 3, 2008
Jiangsu Simcere’s Endostar and Merck KGaA’s Erbitux Are the Targeted Therapies Prescribed Most Often by Chinese Physicians for the Treatment of the Disease, According to a New Report by Decision Resources
ASTRAZENECA’S RECENTIN PLUS FOLFOX4 TO EARN 10 PERCENT PATIENT SHARE IN THE TREATMENT OF COLORECTAL
April 2, 2008
Physicians Indicate that Most Emerging Therapies Will Not Match the Current Gold Standard, According to a New Report from Decision Resources
THE EFFECT OF DRUGS FROM NOVARTIS AND SANOFI-AVENTIS ON MORTALITY RATES WILL DRIVE PRESCRIBING DECIS
April 2, 2008
Novartis’s Exforge Will Remain the Clinical Gold Standard Through 2016, According to a New Report from Decision Resources
THE MARKET FOR KINASE INHIBITORS IN CANCER TREATMENT WILL EXPERIENCE STAGGERING GROWTH, INCREASING F
March 27, 2008
Emerging Drugs and Label Expansion of Currently Marketed Agents Will Drive Growth, According to a New Report from Decision Resources
DRUG TREATMENT MARKET FOR OBESITY WILL INCREASE MORE THAN FIVE-FOLD, REACHING $2.7 BILLION IN 2016
March 25, 2008
Growth Will Be Driven by Novel Emerging Therapies, Including Drugs from Arena and Amylin, According to a New Report from Decision Resources
ASTRAZENECA’S ZACTIMA WILL EARN ALMOST FIVE PERCENT PATIENT SHARE IN THE TREATMENT OF NON-SMALL-CELL
March 20, 2008
Physicians Indicate that Most Promising Emerging Therapies Will Not Match the Current Gold-Standard Avastin/Taxol/Paraplatin Regimen’s Efficacy, According to a New Report from Decision Resources
BY 2016, SIGNIFICANT GENERIC EROSION WILL CAUSE SALES OF DYSLIPIDEMIA DRUGS TO DECLINE BY $3.6 BILLI
March 19, 2008
Statins Will Continue to Dominate Market Despite Patent Expiries and Increased Use of Fixed-Dose Combinations, According to a New Report from Decision Resources
ONE-THIRD OF U.S. PRIMARY CARE PHYSICIANS AND CARDIOLOGISTS DO NOT CURRENTLY PRESCRIBE TREATMENT TO
March 19, 2008
Although Two-Thirds of Surveyed Physicians Anticipate an Increase in the Number of Patients Treated for Low HDL Over the Next Two years, 19 Percent of Surveyed MCOs Will Not Add Novel HDL Drugs to Their Formularies, According to a New Report from Decision Resources
DECISION RESOURCES, INC. ACQUIRES FINGERTIP FORMULARY
March 17, 2008
Acquisition Expands Decision Resources, Inc.’s Offering to Include the Most Accurate, Comprehensive Formulary Solutions on the Market Today
CURRENT AND EMERGING THERAPIES HAVE NO ADVANTAGE OVER PFIZER’S LYRICA IN THEIR EFFECT ON PATIENTS’ Q
March 13, 2008
However, Owing to Safety and Delivery End Points, Drugs from Eli Lilly and Boehringer Ingelheim Will Remain as the Gold Standard Treatments, According to a New Report from Decision Resources
Read More
TEVA PHARMACEUTICAL’S ALTERED PEPTIDE LIGAND COPAXONE BOASTS THE GREATEST PATIENT SHARE AMONG FIRST-
March 11, 2008
Lack of Flulike Side-Effects Drives Physician Prescribing of Copaxone over an Interferon-Beta Therapy, According to a New Report from Decision Resources
NEWLY LABELED THERAPIES FOR NEUROPATHIC PAIN, INCLUDING DRUGS FROM PFIZER AND ELI LILLY, WILL DRIVE
March 10, 2008
Following Recovery From Withdrawals of Two COX-2 Inhibitors, the Chronic Pain Drug Market Will Regain Momentum, According to a New Report from Decision Resources
A DRUG WITH EFFICACY SUPERIOR TO THAT OF MEMANTINE WOULD EARN UP TO A 50% PATIENT SHARE IN THE MODER
March 6, 2008
A Drug’s Effect on Cognitive Decline is the Most Important Attribute Influencing Prescribing Decisions, According to a New Report from Decision Resources
BRISTOL-MYERS SQUIBB AND OTSUKA PHARMACEUTICAL SPEND NEARLY TWICE AS MUCH ON PROMOTION AS OTHER DRUG
March 5, 2008
The New Brands & Strategies: Atypical Antipsychotics Report Provides Critical Commercial Analysis at the Market, Company, and Brand Level
ALTHOUGH REMICADE AND HUMIRA ARE BEING INCREASINGLY PRESCRIBED FOR CROHN’S DISEASE AND ULCERATIVE CO
March 4, 2008
Nearly One-Third of Surveyed Managed Care Organizations Levy Coinsurance Charges and Other Protocols on Remicade and Humira, According to a New Report from Decision Resources
ONCOLOGISTS DESPERATE FOR A DRUG THAT SIGNIFICANTLY INCREASES SURVIVAL RATES IN THE TREATMENT OF ADV
March 3, 2008
Experts are Cautiously Optimistic About Emerging Vaccines, According to a New Report from Decision Resources
A ONCE-DAILY ORAL DRUG FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE THAT TREATS COPD-RELATED INFLAMMATI
February 27, 2008
Although Physicians Report Satisfaction with GlaxoSmithKline’s Advair and Boehringer Ingelheim/Pfizer’s Spiriva, Significant Need Remains for a Novel Anti-Inflammatory Drug, According to a New Report from Decision Resources
COMPETITIVE ADVANTAGES POSITION GLAXOSMITHKLINE’S NOVEL COMBINATION THERAPY TO OVERTAKE AVODART AS T
February 26, 2008
A Drug with a Lower Incidence of Sexual Side Effects Would Require Improved Efficacy Over Existing Therapies, According to a New Report from Decision Resources
UPTAKE OF BRANDED AGENTS WILL DRIVE THE SYSTEMIC LUPUS ERYTHEMATOSUS DRUG MARKET TO QUADRUPLE TO $1.
February 25, 2008
Entry of Novel Therapies Including Rituxan/MabThera and Increased Uptake of CellCept Will Provide Effective Treatment Options, According to a New Report from Decision Resources
IN COMBINATION WITH FOLFOX4, THE EFFECT OF ERBITUX AND AVASTIN ON SURVIVAL RATES WILL DRIVE PRESCRIP
February 22, 2008
Following its Approval, Erbitux Will Earn Gold-Standard Status in 2011, According to a New Report from Decision Resources
Read More
JAPAN BACKS AWAY FROM MAKING REAL CHANGES TO ITS RX PHARMA PRICING MECHANISM
February 19, 2008
Proposed Changes Focus on Raising Price Premiums While Cutting Prices for Existing Drugs, According to a New Macroview Update from Decision Resources
CENTOCOR/JANSSEN-CILAG’S USTEKINUMAB WILL BECOME THE GOLD STANDARD FOR PSORIASIS BY 2011
February 13, 2008
Competitive Advantages in Efficacy Will Drive Prescription Rates, According to a New Report from Decision Resources
DESPITE ONCOLOGISTS’ WILLINGNESS TO PRESCRIBE AVASTIN FOR TREATMENT OF BREAST CANCER, THE FDA IS LIK
February 11, 2008
Seventy-nine Percent of U.S. Oncologists Currently Use Avastin to Treat the Disease, According to a New Macroview Update from Decision Resources
LIPITOR’S SUPERIOR EFFECT ON MORTALITY OVER SALES-LEADING PLAVIX IS DRIVING PRESCRIBING DECISIONS FO
February 11, 2008
Specialists Consider deCode Genetics’ DG-041 Positioned to Replace the Leading Antiplatelet Agent, According to a New Report from Decision Resources
FLURIZAN’S EFFECT IN DELAYING PROGRESSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER’S DISEASE IS S
February 5, 2008
Following its Launch in 2010, Myriad Genetics’ Flurizan Will Earn a 23% Patient Share in the United States, According to a New Report from Decision Resources
EISAI/PFIZER’S ARICEPT OWNS A DOMINATING 42.4% PATIENT SHARE FOR FIRST-LINE TREATMENT OF ALZHEIMER’S
February 4, 2008
Physician Familiarity and its Better Side-Effect/Safety Profile are Driving Aricept Prescription Rates, According to a New Report from Decision Resources
PHYSICIANS STILL HOPEFUL ABOUT DESMOTEPLASE FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE DESPITE NEGAT
January 30, 2008
Surveyed Neurologists Identify a Six-Hour Treatment Window as Area of Greatest Dissatisfaction, According to a New Report from Decision Resources
NEW DRUG FROM SCHERING-PLOUGH/NOVARTIS WILL BECOME THE CLINICAL GOLD STANDARD FOR ASTHMA BY 2011
January 28, 2008
Advantages in Drug Delivery Will Drive Prescription Rates, According to a New Report from Decision Resources
EFFICACY AND FAMILIARITY ARE KEY REASONS PHYSICIANS PRESCRIBE GLAXOSMITHKLINE’S ADVAIR FOR THE TREAT
January 16, 2008
AstraZeneca’s Symbicort Is Gaining Favor Among Physicians for Use in the Treatment of the Diseases, According to New Reports from Decision Resources
PATENT EXPIRIES OF KEY THERAPIES, INCLUDING DRUGS FROM GLAXOSMITHKLINE AND ROCHE, WILL CUT THE CHRON
January 16, 2008
Current Evidence on Emerging Therapies Shows No Significant Improvements Over Existing Drugs, According to a New Report from Decision Resources